Neurocrine Biosciences | NBIX - Ordinary Share Capital


Neurocrine Biosciences reported $100.1M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Acadia Pharmaceuticals USD 168.71M 104K Sep/2025
Agios Pharmaceuticals USD 58.45M 169K Dec/2025
ALKERMES USD 165.1M 49K Sep/2025
Alnylam Pharmaceuticals USD 132.38M 585K Dec/2025
Amgen USD 539M 1000K Dec/2025
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 192.3M 201K Dec/2025
Cytokinetics USD 122.12M 2.52M Sep/2025
Enanta Pharmaceuticals USD 212K 1000 Dec/2023
Exelixis USD 268.1M 2.03M Sep/2025
Gilead Sciences USD 1.24B 1000K Dec/2025
Halozyme Therapeutics USD 117.78M 259K Dec/2025
Incyte USD 198.46M 2.33M Dec/2025
Ionis Pharmaceuticals USD 161.14M 160.98M Sep/2025
Nektar Therapeutics USD 19K 0 Sep/2024
Neurocrine Biosciences USD 100.1M 400K Dec/2025
Pfizer USD 5.69B 1000K Sep/2025
Prothena USD 53.83M 53.29M Sep/2025
Regeneron Pharmaceuticals USD 105.3M 1.1M Sep/2025
Repligen USD 56.28M 30K Sep/2025
Rigel Pharmaceuticals USD 17K 158K Jun/2024
Sarepta Therapeutics USD 104.77M 7.06M Sep/2025
Teva Pharmaceutical Industries USD 1.15B 0 Dec/2025
Ultragenyx Pharmaceutical USD 96.44M 88K Sep/2025
Vertex Pharmaceuticals USD 254M 0 Dec/2025
Xoma USD 87K 1000 Jun/2024